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Background: The dynamic interaction between HIV and its host governs the replication of the virus and the study
of the virus-host interplay is key to understand the viral lifecycle. The host factor lens epithelium-derived growth
factor (LEDGF/p75) tethers the HIV preintegration complex to the chromatin through a direct interaction with
integrase (IN). Small molecules that bind the LEDGF/p75 binding pocket of the HIV IN dimer (LEDGINs) block HIV
replication through a multimodal mechanism impacting early and late stage replication including HIV maturation.
Furthermore, LEDGF/p75 has been identified as a Pol interaction partner. This raised the question whether LEDGF/p75
besides acting as a molecular tether in the target cell, also affects late steps of HIV replication.
Results: LEDGF/p75 is recruited into HIV-1 particles through direct interaction with the viral IN (or Pol polyprotein) and
is a substrate for HIV-1 protease. Incubation in the presence of HIV-1 protease inhibitors resulted in detection of
full-length LEDGF/p75 in purified viral particles. We also demonstrate that inhibition of LEDGF/p75-IN interaction
by specific mutants or LEDGINs precludes incorporation of LEDGF/p75 in virions, underscoring the specificity of
the uptake. LEDGF/p75 depletion did however not result in altered LEDGIN potency.
Conclusion: Together, these results provide evidence for an IN/Pol mediated uptake of LEDGF/p75 in viral particles
and a specific cleavage by HIV protease. Understanding of the possible role of LEDGF/p75 or its cleavage fragments in
the viral particle awaits further experimentation.
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Replication of the human immunodeficiency virus type-1
(HIV-1) is characterized by a dynamic interplay between
the virus and the infected cell with a specific temporal
and spatial regulation of the virus-host protein-protein
interaction (PPI) network. Integration of lentiviral gen-
omic DNA into host chromatin is directed by the viral
integrase (IN) and the cellular cofactor lens epithelium-
derived growth factor (LEDGF/p75) [1-5], a transcrip-
tional co-activator that tethers a variety of proteins to
the chromatin [6-10]. Whereas the N-terminal PWWP
domain of LEDGF/p75 reads chromatin modifications
[11-13], the C-terminal integrase binding domain (IBD)
interacts with lentiviral IN [14]; together they direct* Correspondence: zeger.debyser@med.kuleuven.be
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unless otherwise stated.integration into active transcription units [2,15-18]. As a
molecular tether and a targeting determinant, LEDGF/
p75 is recognized as a crucial cellular cofactor of HIV
infection, although the related Hepatoma-derived growth
factor Related-Protein 2 (HRP-2) can substitute for
LEDGF/p75 in its absence [17,19,20]. Additionally,
LEDGF/p75 has been shown to interact with the HIV-1
Pol precursor protein in Jurkat cells [21].
In 2010 structure-based drug design has led to the dis-
covery of small molecules that bind in the LEDGF/p75
binding pocket of the IN catalytic core dimer and inhibit
HIV replication [22], referred to as LEDGINs (small
molecules binding to the LEDGF/p75 binding pocket of
integrase). Similar molecules were later reported by
other groups [23-27]. LEDGINs disrupt the interaction
of IN with LEDGF/p75 and act as allosteric IN inhibi-
tors. The latter mechanism of action is attributed to
enhanced IN multimerization [23-25,28,29]. Unexpect-
edly, LEDGINs also affect late stage HIV replicationral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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LEDGINs displaying severe replication defects at the
level of reverse transcription (RT), nuclear import and
integration [30,32,33]. Although packaging of genomic
RNA and proteolytic maturation of the virus are not af-
fected, a large proportion displays morphological defects
in electron microscopy (EM) [30,32,33]. The phenotype
requires the binding of LEDGINs to the LEDGF/p75
binding pocket in IN [24,30] and is mediated by en-
hanced multimerization of IN in the viral particles, as
shown by 3 independent groups [30,32,33].
Interestingly, in a parallel approach peptides that bind
LEDGF/p75 and disrupt the interaction with IN were
identified by phage-display [34]. Expression of these
LEDGF/p75-interacting cyclic peptides impeded HIV rep-
lication. Mechanism of action studies revealed that the
peptides block integration and reduce infectivity of virus
produced in cells that constitutively express the active
peptide without affecting proteolytic maturation [34].
Together these observations led us to hypothesize that
LEDGF/p75 may be present in the viral particle, play a
role in late stage replication and hence influence LEDGIN
potency. Here, we present strong evidence for a specific
IN (Pol)-mediated uptake of LEDGF/p75 in HIV particles
and its cleavage by HIV protease. We also demonstrate
that the late stage potency of LEDGINs is not affected by
the presence of LEDGF/p75. Understanding of the pos-
sible role of LEDGF/p75 or its cleavage fragments in the
HIV particle awaits further experimentation.
Results
LEDGF/p75 is incorporated in HIV-1 particles and is a
substrate of HIV-1 protease
We purified and concentrated HIV-1 particles by ultra-
centrifugation using a step gradient of 6% to 20% Iodixa-
nol (Optiprep™) in PBS [35] (Figure 1A). Exosomes are
hard to distinguish from HIV particles as for their com-
position and physical properties [35,36]. Our method
separates viral particles from exosomes/microvesicles as
shown by the distinct peaks of p24 antigen and acetyl-
cholinesterase activity, respectively, following velocity gra-
dient purification (Figure 1B). To evaluate LEDGF/p75
incorporation into the virions, we performed Western blot
analysis on the individual fractions from the virus purifica-
tion and the pooled, concentrated viral fractions (fraction
8–10) (Figure 1C). In the individual fractions IN and
CA were readily detected; however, LEDGF/p75 was
identified only in the pooled and additionally concen-
trated fraction using a specific LEDGF/p75 antibody
(A300-848A, C-terminal epitope). This suggests that
LEDGF/p75 is present in low abundance in the virions.
Alternatively, the low avidity of the LEDGF/p75 anti-
body may explain the difficulty to detect the protein.
Purified virus-containing fractions were additionallytreated with subtilisin, a non-specific protease, to re-
move proteins associated with the envelope of the viral
particle and to exclude LEDGF/p75 contamination.
Purity of the fractions was corroborated by EM analysis
(Figure 1D). However, minor contamination of these
virus preparations with exosomes/microvesicles cannot
be excluded.
Interestingly, apart from the 75 kDa band representing
full-length LEDGF/p75 (Figure 1E, lane 1, closed arrow-
head), smaller protein bands of different molecular
weights were detected with the same anti-LEDGF/p75
antibody (Figure 1E, lane 1). Remarkably, following incu-
bation of virus preparations with subtilisin (at 37°C for
18 h), only the smaller protein bands were detected with
the same C-terminal antibody (Figure 1E, lane 2). This
data suggest that the co-purified full-length LEDGF/p75
in the non-treated samples may have been a contamin-
ant that is bound to the envelope of the virions and is
partially digested by the non-specific protease subtilisin
or that subtilisin may have non-specifically cleaved intra-
virion LEDGF/p75. Alternatively, prolonged exposure of
LEDGF/p75 to HIV-1 protease (PR) in fully mature par-
ticles may have led to proteolytic cleavage of intravirion
LEDGF/p75 by PR.
In order to address these issues and to verify our hy-
pothesis, we performed a series of experiments. First, to
verify the efficiency of removal of contaminating proteins
and cellular debris by subtilisin treatment, we spiked virus
preparations with recombinant Flag-LEDGF/p75 and per-
formed subtilisin treatment. As expected, the exogenously
added recombinant Flag-LEDGF/p75 was not detected by
Flag antibody, indicating that subtilisin can completely de-
grade and remove any contaminating proteins from viral
particles in our experimental system (Additional file 1:
Figures S1A, S1B). Because exosomes and viral particles
have comparable physical properties and are surrounded
by a membrane, we had to rule out the contribution of
cellular contaminants. After performing the same purifica-
tion and sample processing, we only detected LEDGF/p75
fragments in viruses purified from MT-4 cells, a T-cell
line, but not in the supernatant of uninfected control cells
(Additional file 2: Figure S2), further indicating that
LEDGF/p75 detected in the purified virion is not a con-
taminant. Second, in order to investigate the effect of sub-
tilisin against intravirion proteins, we evaluated the level
of viral proteins by Western blot analysis. The levels of IN
and CA were similar with or without subtilisin treatment
(Figure 1E), indicating that intravirion proteins are indeed
protected from subtilisin degradation. Moreover, because
subtilisin proteolysis is unaffected by ritonavir (RTV)
treatment (Additional file 1: Figure S1A), the observed
bands in Figure 1E (lane 2) are not proteolytic products of
subtilisin treatment. Finally, we produced virus in the
presence of 0.3 μM (6x IC50) RTV (PR inhibitor) and
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Figure 1 LEDGF/p75 is incorporated in HIV-1 particles. (A) Illustration of virus production and purification protocols. (B) Distribution of
exosomes and HIV fractions: Exosomes as assessed by acetylcholinesterase (AChE) activity and HIV-1 as detected by p24 ELISA were effectively
separated by velocity gradient purification (mean values ± standard deviations; n = 6). (C) Western blot analysis of individual fractions, pooled
fractions 8–10 (delineated with a broken line) and producer cell lysate. (D) Negative staining electron microscopy (EM) of HIV fractions 8–10 purified in
a Iodixanol step gradient with or without subtilisin treatment. Staining was performed with 0.5 phosphortungstic acid pH 7.2. (scale bar = 500 nm)
(E) Western blot analysis of purified virus: Untreated virus is shown in lane 1, subtilisin treated virus in lane 2, subtilisin treated virus produced
in presence of ritonavir (RTV) (added 6 hours post transfection) in lane 3 and subtilisin treated virus with RTV added during virus production
and purification in lane 4. Immunoblots for IN and p24 are included as control, and indicate equal loading of the samples. Full length LEDGF/p75 is
indicated by an arrowhead. Lanes 1–2 were run on a 12.5% gel, lanes 3–4 on a 4-12% gel with appropriate MW markers.
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LEDGF/p75 was readily detected by Western blot analysis
in samples treated with RTV during virus production
(Figure 1E, lane 3), and was even more prominent when
RTV treatment continued during purification steps too
(Figure 1E, lane 4). To corroborate this, we performedMass spectrometry analysis from RTV treated purified
viruses and we were able to detect and identify LEDGF/
p75 peptides (Additional file 3: Table S1, Additional file 4:
Figure S3). Taken together, these observations point to-
wards the incorporation of LEDGF/p75 in HIV parti-
cles. Furthermore, our data show that LEDGF/p75 is a
Desimmie et al. Retrovirology  (2015) 12:16 Page 4 of 15substrate of HIV-1 PR irrespective of the virus producer
cell lines used. Of note, only bands corresponding to
IN and CA and not those of gag-products are shown to
simplify the analysis. Although p24-values from virus
treated with 0.3 μM RTV dropped 1 log compared to
non-treated virus (as measured by 24-ELISA), we were
able to detect IN and CA, since a substantial amount of
virus (30 μg) was utilized for Western Blot analysis.
Normalization of the virus preps was performed on
protein content (BCA) and not on p24 content.
Identification of HIV-1 protease cleavage sites in
LEDGF/p75
To further characterize LEDGF/p75 as a substrate of
HIV-1 PR, we performed HIV-1 PR-mediated limited
proteolysis of recombinant (Flag)-LEDGF/p75 (Figure 2,
Additional file 5: Figure S4). Combining Coomassie
staining and Western blot analysis with anti-LEDGF/p75
(C-terminal epitope) or anti-Flag (N-terminal tag) anti-
body, we detected HIV-1 PR generated LEDGF/p75 frag-
ments with apparent molecular masses of 11, 13, 14, 19,
27, 34, 44 and 65 kDa (Figures 2A, 2B, S4A, S4B). RTV
protected LEDGF/p75 against proteolysis by PR in a
concentration dependent manner (Figure 2C), corrobor-
ating our observation for intravirion LEDGF/p75 cleav-
age (Figure 1E). The RTV concentration required to
inhibit LEDGF/p75 proteolysis by HIV-1 PR is higher
than the concentration we normally use for its antiviral
activity. In the same in vitro assay, we evaluated the
cleavage of recombinant His-MBP-sPol_PRD25N (equal
mass percentage as used for Flag-LEDGF/p75) by adding
active PR in trans with or without RTV. Once again,
complete inhibition of PR is achieved only at 10 μM of
RTV, suggesting that in our experimental system irre-
spective of the substrate nature a higher concentration
of RTV is required to completely block PR (Additional
file 5: Figure S4C). As an internal control we used the
globular protein BSA, which is not cleaved by PR
(Figure 2A,C).
Using HIVcleave, a HIV PR cleavage prediction program
[38], we found several predicted cleavable octapeptides in
LEDGF/p75 (data not shown). We then subjected highly
purified recombinant LEDGF/p75 to HIV-1 PR proteoly-
sis. We identified and sequenced 5 prominent protein
bands of HIV-1 PR-derived fragments of recombinant
LEDGF/p75 (Figure 2D) and mapped the HIV-1 PR
cleavage sites to the predicted cleavage sites (Figure 2D,
Additional file 5: Figure S4D, Additional file 3: Tables
S2 and S3). In an attempt to correlate these findings
with the fragments observed in lane 2 in Figure 1E, we
focused on the two small fragments below 25 kDa. Tak-
ing into account that these fragments are identified in
Western blot analysis using a LEDGF/p75 specific anti-
body that recognizes the C-terminal end (marked inFigure 2D), the two bands below the 25 kDa marker in
the second lane of Figure 1E may correspond to the
10.5 and 19.2 kDa (LEDGF357–530) fragments. Of note,
none of the HIV-1 PR cleavage sites on LEDGF/p75
overlap with the described sites for caspase-3 and −7
[39] (Additional file 3: Table S4).LEDGF/p75 is recruited into the viral particle through
interaction with HIV integrase
To evaluate how LEDGF/p75 is recruited into the viral
particle, we produced and purified a previously described
NL4.3_INW131A mutant virus that carries a W131A substi-
tution in IN disrupting the interaction between LEDGF/
p75 and IN [40]. In contrast to WT virus, neither full-
length LEDGF/p75 nor HIV-1 PR-derived LEDGF/p75-
derived fragments were detected in NL4.3_INW131A virus
produced in the presence of RTV (Figure 3A). Recipro-
cally, we stably back-complemented LEDGF/p75 depleted
293T cells with either Flag-tagged LEDGF/p75 (Flag-
LEDGF/p75BC) or the D366N mutant that is unable to
interact with IN (Flag-LEDGF/p75BCD366N). Expres-
sion was monitored by confocal microscopy, qPCR and
Western blotting (Additional file 6: Figures S5A-C). We
produced NL4.3, taking 293T WT cells along as control
(designated as WT in Figure 3B lane 1) [41]: WT
LEDGF/p75 and Flag-LEDGF/p75BC were incorporated
into the virion, whereas Flag-LEDGF/p75BCD366N was
not (Figure 3B). Since LEDGF/p75 is known to interact
with IN through its C-terminal part, we also evaluated vir-
ion incorporation of eGFP-LEDGF325–530, using WT cells
expressing eGFP-LEDGF325–530 or eGFP-LEDGF325-530
D366N (Figure 3C, Additional file 6: Figure S5D-F). The
prominent ~60 kDa band observed corresponds to eGFP-
LEDGF325–530. Also smaller degradation products were
detected. The endogenous LEDGF/p75 fragments were
detected in WT 293T controls at higher exposure (data
not shown). Together, these data support recruitment
of LEDGF/p75 into viral particles through direct inter-
action with IN.
To further verify the specificity of LEDGF/p75 incorpor-
ation in the virions, we produced virus in the presence of
LEDGIN CX05045 (10 μM), raltegravir (0.06 μM) or RTV
(0.3 μM) and determined LEDGF/p75 incorporation into
the virions. Less LEDGF/p75 was incorporated when virus
was produced in the presence of CX05045 compared with
viruses produced in the presence of DMSO, raltegravir
or RTV (Figure 3D). Note, that since RTV was not
present, detection of full-length LEDGF/p75 was pre-
cluded (Figure 3D, lanes 1–3). Finally, we produced
NL4.3_INA128T virus, a virus resistant to CX05045, in
the presence or absence of the compound, and demon-
strated that CX05045 did not inhibit LEDGF/p75 incorp-
oration into NL4.3_INA128T particles (Figure 3E), further
Figure 2 (See legend on next page.)
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Figure 2 Proteolytic cleavage sites of LEDGF/p75 by HIV-1 protease (PR). Recombinant LEDGF/p75 proteolysis by HIV-1 PR over a period of
2 hours by (A) Coomassie staining after SDS-PAGE and by (B) immunoblotting using anti-LEDGF/p75 antibody (A300-848A). (C) Addition of
Ritonavir (RTV) inhibits Flag-LEDGF/p75 proteolysis by HIV-1 protease in a concentration dependent manner as shown by Coomassie staining.
(D) Schematic representation of full length LEDGF/p75, HIV-1 PR cleavage sites confirmed by N-terminal protein sequencing (red arrow-heads)
and the resulting fragments. The antibody epitope is marked. Coomassie stained gel of LEDGF/p75 cleavage products with the indicated molecular
mass calculated based on their relative mobility (estimated weight) [37]. Arrowheads indicate bands representing BSA (grey), LEDGF/p75 full
length (black) and HIV PR (open arrowheads) in A, C and D.
Desimmie et al. Retrovirology  (2015) 12:16 Page 6 of 15indicating that LEDGF/p75 recruitment into HIV-1 parti-
cles is specific and depends on interaction with IN.
Finally, we estimated the ratio of LEDGF/p75 and
eGFP-LEDGF325–530 to IN in the virions (Additional file
7: Figures S6A, S6B). The stoichiometry of LEDGF/p75
to IN and eGFP-LEDGF325–530 to IN were approximately
1:250 and 1:140, respectively. However, it is important to
take into consideration that the effect of PR-mediated
degradation of full-length LEDGF/p75 confounds this
analysis leading to underestimation of the protein.
Nevertheless, these results suggest that LEDGF/p75 is
specifically recruited by IN and that abrogation of the
LEDGF/p75-IN interaction in virus producer cells inter-
feres with the uptake of LEDGF/p75 in the virion.
LEDGF/p75 interacts with the HIV-Pol polyprotein
We demonstrated that recruitment of LEDGF/p75 into
HIV virions requires interaction with IN. Moreover, it is
known that LEDGF/p75 interacts with the catalytic core
of IN [41]. This would imply that IN dimers are pre-
formed at the precursor (Gag)-Pol polyprotein level in
virus producing cells. In fact, we and others have re-
cently shown that LEDGINs bind HIV-1 Pol polyprotein
and enhance IN/Pol multimerization [30,32,33]. More-
over, in a recent global virus-host interaction proteomics
analysis, LEDGF/p75 was identified as one of the host
proteins co-immunoprecipitated with HIV-1 Pol poly-
protein [21]. We analyzed the interaction between HIV-
1 Pol polyprotein and LEDGF/p75 by AlphaScreen using
recombinant Glutathione S-Transferase tagged (GST)-
Pol polyprotein with a catalytically dead PRD25N (GST-
sPol_PRD25N) and Flag-LEDGF/p75. We observed direct
and specific binding between LEDGF/p75 and Pol with
an apparent Kd of 3.1 ± 1.1 nM and a Hill coefficient of
0.65 ± 0.08 (Figure 4A), indicating negative cooperativity.
Considering that the LEDGF/p75 binding requires an IN
dimer interface, these results suggest the existence of
one high and one low affinity LEDGF/p75 binding site
on a Pol dimer. In contrast, LEDGF/p75D366N failed to
interact (Figure 4A), corroborating specificity of the
assay and the findings in the virion (Figure 3B). Next, we
evaluated the effect of CX05045, raltegravir or DMSO on
the LEDGF/p75-Pol interaction (Figure 4B). CX05045
inhibited the LEDGF/p75-Pol interaction in a concentra-
tion dependent manner with an IC50 of 10.7 μM (95% CI9.5-12.0) and a Hill coefficient of 1.0. Neither DMSO nor
raltegravir affected the interaction. In pull-down assays we
also observed that Flag-LEDGF/p75, but not Flag-LEDGF/
p75D366N interacts with His-MBP-tagged synthetic Pol
polyprotein (Figure 4C: His-MBP-sPol_PRD25N).
Overall, on the basis of the direct interaction between
HIV-1 Pol polyprotein and LEDGF/p75 in vitro, along
with the requirement of IN (Pol) interaction for virion
incorporation of LEDGF/p75 in the virus producer cells,
we conclude that LEDGF/p75 can be specifically incor-
porated into the virions through an interaction with
either IN or its precursor Pol protein.
LEDGIN potency is independent of the presence of
LEDGF/p75 in virus producer cells
As LEDGF/p75 incorporation into viral particles was
hampered by LEDGIN CX05045, we investigated if LED-
GIN potency at the late stage is dependent on the pres-
ence of LEDGF/p75 fragments in viral particles. Therefore
we infected TZM-bl cells, containing a HIV-1 LTR driven
luciferase reporter gene, with NL4.3 produced in LEDGF/
p75KD or WT 293T cells with or without 0–13.5 μM
CX05045. CX05045 reduced virus infectivity irrespective
of the presence of LEDGF/p75 in virus producing cells
(Table 1), excluding a major contribution of LEDGF/p75
to the potency of LEDGINs on late stage HIV replication.
These data are in agreement with previous reports
[26,32,33,42]. Furthermore, the absence of LEDGF/p75 in
virus producer cells did not result in major defects in virus
infectivity (Figure 5A) or morphological impairments
(Figure 5B, 5C). Likewise, HIV−, virus produced on
LEDGF/p75 knock out cells (Nalm−/−), showed only mod-
est defects in replication capacity compared to HIV+, virus
produced on WTcells (Nalm+/c).
Together these data suggest that the recruitment of
LEDGF/p75 into viral particles seems not an essential
process for generation of infectious particles or late stage
LEDGIN potency.
Discussion
The interaction of LEDGF/p75 with HIV-1 Pol [21], the
observations on the late stage effect of LEDGINs
[24,30-33], and our data on cyclic peptides binding to
LEDGF/p75 [34], prompted us to investigate if LEDGF/
p75 is incorporated in viral particles. Our study revealed
Figure 3 LEDGF/p75 is recruited by integrase (Pol) into the HIV-1 particle. (A-E) Western blot analysis of various, independently purified
and subtilisin-treated virus preparations using specific antibodies to detect LEDGF/p75, IN or CA. (A) NL4.3 and NL4.3_INW131A produced in
presence of ritonavir on 293T cells and purified. (B) NL4.3 produced in WT 293T cells (WT), 293T LEDGF/p75 KD cells complemented with
either Flag-LEDGF/p75BC or Flag-LEDGF/p75BCD366N. (C) NL4.3 produced in 293T WT cells stably expressing either eGFP-LEDGF325–530 or
eGFP-LEDGF325-530D366N. (D) NL4.3 produced in 293T cells in the presence of DMSO, CX05045, raltegravir or ritonavir (E) NL4.3_INA128T produced in
the presence or absence of CX05045.
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Figure 4 Interaction between LEDGF/p75 and HIV Pol. Direct interaction of LEDGF/p75 with HIV-1 Pol polyprotein as determined by an
AlphaScreen PPI assay. (A) Titration of Flag-LEDGF/p75WT or Flag-LEDGF/p75D366N against 20 nM GST-sPol_PRD25N. LEDGF/p75WT binds Pol with
an apparent KD of 3.1 ± 1.1 nM, whereas the D366N point-mutation abolishes interaction. (B) Titration of CX05045, raltegravir (RAL) and DMSO
against a constant background of 5 nM Flag-LEDGF/p75WT and 20 nM GST-Pol_PRD25N. CX05045 inhibit the interaction with an IC50 of 10.7 μM
(95% CI 9.5-12.0). Data represent mean values ± standard deviations of duplicate measurements in a representative experiment. (C) Pull-down of
His-MBP-sPol_PRD25N using recombinant Flag-LEDGF/p75WT or Flag-LEDGF/p75D366N.
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in an IN-dependent manner and that LEDGF/p75 is an
authentic substrate of HIV-1 PR. We provide evidence
that LEDGF/p75 already interacts with IN when part of
the Pol polyprotein, probably driving the specific incorp-
oration of LEDGF/p75 in HIV virions. Intravirion
LEDGF/p75 did not alter the apparent potency of LED-
GINs during late stage infection. No drastic impact of
intravirion LEDGF/p75 on HIV infectivity in cell lines
could be demonstrated so far.Table 1 The potency of LEDGINs is not affected by the
presence of LEDGF/p75 HIV producer cells
Producer cell line EC50 CX05045 (μM)
1
WT 0.6 (95% CI: 0.5-0.8)
LEDGF/p75KD 0.8 (95% CI: 0.6-1)
1Effective concentration in μM required to reduce Tat-driven firefly luciferase
activity by 50% in TZM-bl cells at 40 hpi. The table shows means and the 95%
confidence interval (95%CI).In a series of experiments, we revealed that LEDGF/
p75 can be detected in highly purified HIV virions
(Figure 1), and is a substrate for HIV PR, as we detected
several HIV-1 PR-derived LEDGF/p75 fragments in puri-
fied virus preparations. Addition of the PR inhibitor,
RTV, allowed detection of full-length LEDGF/p75 in
these virus particle preparations (Figures 1 and 2). We
identified HIV PR cleavage sites for the prominent
fragments using N-terminal sequencing (Figure 2,
Additional file 5: Figure S4, Additional file 3: Table S3),
even though multiple other sites can be identified by
HIVcleave prediction. LEDGF/p75 fragments were ab-
sent or diminished in viruses containing INW131A, an
IN mutant incapable of binding to LEDGF/p75, or in
viruses produced from cells expressing mutant LEDGF/
p75BCD366N, defective for interaction with HIV-1 IN
(Figure 3). Furthermore, as PR is unlikely to be active
prior to assembly to generate mature Gag and Pol prod-
ucts, the direct interaction between LEDGF/p75 and HIV-
Figure 5 Effect of LEDGF/p75 on replication capacity of newly produced HIV-1 virions. (A) Replication of HIV+ (virus produced in WT Nalm
6 cells) and HIV− (virus produced on Nalm−/− cells), after normalization for p24, was monitored in Nalm+/c cells by p24 ELISA. (B) Thin section
TEM images of HIV-1 particles generated by NL4.3 infected Nalm+/c or Nalm−/− cells. Arrows indicate immature particles (scale bar = 200 nm).
(C) Viral particles were classified into mature particles with conical capsid (black bars), immature particles (white bars), and budding particles
(gray bars), and the percentage of each category was calculated relative to the total number of particles (HIV−; 150, HIV+; 350 viral structures per
condition) analyzed.
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immature virion preparations produced in presence of
RTV are compatible with the requirement of a LEDGF/
p75-Pol interaction for virion incorporation. We propose
a model whereby LEDGF/p75 is incorporated in HIV vi-
rions through an interaction with dimeric IN core domain,
already present in a Pol polyprotein dimer. Although
LEDGF/p75 is a nuclear protein, it is synthesized in the
cytoplasm and other examples of nuclear proteins that are
detected in purified HIV particles exist. Such proteins in-
clude INI-1 [43], Ku70 [44], Ku80 and U5 small nuclear
ribonucleoprotein [45]. Moreover, although detection of
LEDGF/p75 in the supernatant of cell cultures (Figure 1)
may result from cell damage, LEDGF/p75 and related
HRP-proteins have been shown to be secreted [46,47].
Although more than 300 human proteins have been
identified in HIV viral particles (summarized in [48],
reviewed in [36]), LEDGF/p75 has not been detected[36,45,48,49]. HIV protease-mediated cleavage of LEDGF/
p75 might be responsible for this lack of detection. Poor
avidity of the available LEDGF/p75 antibodies hampers
the detection in immunoblots requiring the use of large
amounts of concentrated virions. Furthermore, the low
abundance of LEDGF/p75 in viral particles (Additional
file 7: Figure S6) prompted us to use a specific approach
for the MS analysis, focusing on part of the SDS-page gel
corresponding to 75 kDa proteins for MS-analysis.
Nevertheless, taking into account the number of Pol
molecules per virion, we estimate that only 1 to 2.5 mole-
cules of LEDGF/p75 are present per viral particle. It is es-
timated that there are ~5,000 copies of Gag molecules per
immature virion with a Gag-Pol to Gag ratio of 1:10 to
1:20. Considering 100% efficiency of proteolytic matur-
ation of the precursor Gag-Pol and Pol polyproteins, there
would be a maximum of 250 to 500 copies of RT and IN
[50]. We estimate the LEDGF/p75 to IN in the range of
Desimmie et al. Retrovirology  (2015) 12:16 Page 10 of 151:250, estimated by semiquantitative immunoblot analysis,
although PR cleavage may result in an underestimation of
the absolute amount of LEDGF/p75. In any case, even
though the detected intravirion LEDGF/p75 appears spe-
cifically incorporated and not the result of a contamin-
ation, only few LEDGF/p75 molecules would be present
per viral particle.
Although we show that LEDGINs hamper LEDGF/p75
incorporation in the viral particle (Figure 3D), NL4.3
virus produced in LEDGF/p75KD cell lines showed a
similar sensitivity to LEDGINs compared to virus pro-
duced on WT cells (Table 1). Similar results were ob-
tained by Balakrishnan et al. [33], Jurado et al. [32],
Fadel et al. [42] and Sharma et al. [26]. LEDGINs do en-
hance IN multimerization in the absence of LEDGF/p75.
Since a relatively high concentration of CX05045 (10-
fold higher than for IN) seems to be required to displace
LEDGF/p75 from Pol polyprotein (Figure 3C), a more
subtle contribution of virion incorporated LEDGF/p75
to the mechanism of action of LEDGINs cannot be
excluded.
LEDGF/p75 depletion in HIV-producer cells did not
lead to aberrant morphological changes in virus particles
as detected by TEM (Figure 5B,C) and no major reduction
in viral infectivity (Figure 5A), as reported before [42].
Conclusion
In conclusion, we show that LEDGF/p75 is specifically
recruited by IN/Pol into HIV-1 particles and that
LEDGF/p75 is a substrate for HIV-1 protease. So far, no
critical role can be attributed to LEDGF/p75 in the gen-
eration of infectious viral particles. Intravirion LEDGF/
p75 has apparently no major effect on late stage potency
of LEDGINs.
Methods
Reagents
Antiviral compounds: LEDGINs (synthesized by Centre
for Drug Design and Development (CD3), KULeuven
R&D, Leuven, Belgium), AZT, raltegravir and RTV (ob-
tained from the AIDS Research and Reference Reagent
Program, Division of AIDS, NIH).
Chemicals: subtilisin, acetylthiocholine iodide substrate
and 5, 5′-dithiobis-2-nitrobenzoic acid (Ellman’s reagent,
DTNB) (purchased from Sigma-Aldrich, Benelux B.V.,
Belgium).
Antibodies: Anti-LEDGF/p75 (rabbit, A300-848A, Bethyl
laboratories, Montgomery, TX), anti-β-tubulin (mouse, T-
4026, Sigma-Aldrich, St Louis, MO), anti-HIV-1 CAp24
(mouse, #24-2, AIDS Research and Reference Reagent Pro-
gram, Division of AIDS, NIAID, NIH), anti-HIV-1 IN
(mouse, IN-2 (ab66645), Abcam plc, Cambridge Science
Park, Cambridge, UK or monoclonal antibody (8G4) from
Division of AIDS, NIAID, NIH contributed by Dr. Dag E.Helland) and anti-Flag (mouse, M2 monoclonal antibody
(F3165) Sigma-Aldrich, St. Louis, MO, USA) were used.
Cell culture and generation of cell lines
293T, and HeLa TZM-bl (obtained from the AIDS Re-
search and Reference Reagent Program, Division of AIDS,
NIH: TZM-bl from Dr. John C. Kappes, Dr. Xiaoyun Wu
and Tranzyme Inc.) cells were maintained in Dulbecco’s
modified Eagle medium (GIBCO BRL, Merelbeke,
Belgium) supplemented with 8% fetal calf serum (FCS;
Sigma-Aldrich, Bornem, Belgium) and 50 μg/ml genta-
micin (GIBCO BRL). MT-4 and Nalm-6 cells were
grown in RPMI 1640 (GIBCO BRL) supplemented with
12% FCS and 50 μg/ml gentamicin. All cell lines were
grown in a humidified atmosphere with 5% CO2 at 37°C.
A SIV-based lentiviral vector (pGAE SFFV-GFP-IRES-
tCD34-2xshL3mir) was used to create stable LEDGF/
p75KD in 293T cells. pGAE_CAG-eGFP-WPRE [51]
(kind gift from Didier Nègre, Ecole Normale Supérieure,
Lyon) was used as backbone and digested with Esp3I
and BamHI to replace the CMV early enhancer/chicken
β-actin (CAG) promoter by a multiple cloning site (MCS)
containing BsiWI, Eco47III and BamHI restriction sites to
result in pGAE_MCS-eGFP-WPRE, which served as a
backbone for further cloning. Next, eGFP was replaced by
SFFV-ZeoR-IRES-tCD34-2xshL3mir, which was digested
from pCH_SFFV-ZeoR-IRES-tCD34-2xshL3mir [52] using
AgeI and ClaI and ligated into the backbone which was
digested using the same restriction enzymes resulting
in pGAE SFFV-ZeoR-IRES-tCD34-2xshL3mir. The SIV-
based lentiviral vector was produced by transfecting 15 μg
transfer plasmid, 15 μg packaging plasmid and 5 μg
VSV.G envelop plasmid per culture dish carried out as
described before [53]. 293T cells were transduced
at high MOI using pGAE SFFV-ZeoR-IRES-tCD34-
2xshL3mir to create stable LEDGF/p75KD 293T cells.
To generate 3xFlag-LEDGF/p75BC and 3xFlag-LEDGF/
p75BCD366N cell lines, we transduced the LEDGF/
p75KD cells with pCMHWS-3xFlag-LEDGF/p75-IRES-
HygroR and pCMHWS-3xFlag-LEDGF/p75-IRES-HygroR
lentiviral vectors, respectively. LEDGF/p75 expression was
confirmed by immunocytochemistry, Western blot and
RT-qPCR.
Virus production from LEDGF/p75 KO cells
To generate HIV+ and HIV−, 1x106 Nalm+/c and Nalm−/−
cells (as described by Schrijvers et al. [17]) were chal-
lenged with HIV-1NL4–3 at high MOI, washed twice with
PBS after two days and resuspended in culture medium; at
day 7–9 the supernatant was filtered through a 0.45 μm
filter (Millipore) and harvested. Three independent HIV+
and HIV− productions tested pairwise and gave reprodu-
cible results. Genotypically both viruses have WT IN as
verified by sequencing.
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Production of the HIV-1 molecular clone NL4.3 was car-
ried out by transfecting 293T cells as described before
[30,53]. Briefly, 5.5 × 106 cells were plated and trans-
fected with 20 μg of plasmid per cell culture dish in
OptiMEM. The transfection mixture was added directly
on the cells drop by drop. 6 h post transfection, the
transfection medium was replaced with OptiMEM supple-
mented with 50 μg/ml gentamicin. 72 h post transfection,
cell-free supernatant was harvested, filtered through 0.22
μm filters, and used directly or stored at −80°C until use.
Infectivity assays
To determine infectivity, Nalm+/c cells were infected
with equal amounts of viruses normalized for p24 anti-
gen and washed 3 times 6 hours post infection. Virus
replication was monitored by quantifying p24 level in
the supernatant on successive days using p24 ELISA
(Innogenetics, Ghent, Belgium).
To determine the EC50 in TZM-bl cells, 2x10
4 cells
were infected with equivalent amounts of virions pro-
duced in presence of a CX05045 1:3 dilution series. Cells
were lysed in buffer containing 50 mM Tris/HCl, pH
7.3, 200 mM NaCl, 0.2% NP40 and 5% glycerol and ana-
lyzed for firefly luciferase activity (ONE-Glo™, Promega,
Belgium) according to the manufacturer’s instructions.
Readouts were normalized for protein content as deter-
mined by a BCA-assay (BCA Protein Assay Kit, Thermo
Scientific).
Purification of HIV particles
Twenty to twenty-five 10-cm dishes of 80% confluent
293T cells were transfected with NL4.3, NL4.3_INA128T
or NL4.3_INW131A as described above. For some of the
experiments, RTV (300 nM) was added 6 h post transfec-
tion and added during the purification and subtilisin treat-
ment step to prevent LEDGF/p75 cleavage by PR. At 72 h
post transfection, supernatants were harvested and filtered
through 0.22 μm filters (Millipore). Viruses were pelleted
by ultracentrifugation (31,000 rpm, 45 minutes, Ti70 rotor,
Beckman Coulter), resuspended and treated with 500 μl
subtilisin (1 mg/ml) (Sigma, Belgium) in 20 mM Tris–HCl
(pH 8.0), 150 mM NaCl and 1 mM CaCl2 for 18 hours at
37°C to remove any contaminating sticky proteins. Subtili-
sin was inactivated by adding 500 μl of DMEM supple-
mented with 10% FCS, 20 mM EDTA and 5 μg/ml of
PMSF at room temperature for15-30 minutes. The sub-
tilisin treated virus was then applied to an iodixanol
(Optiprep™) step gradient (6–20.4%) and ultracentri-
fuged using the Ti70 rotor (52,000 rpm, 90 minutes).
Fractions were taken from top and one-tenth of the
fractions were immediately used to perform the Ellman
acetylcholinesterase assay [54], while one-twentieth of
the fractions were used for p24 ELISA to distinguishthe fractions containing exosomes and pure viral parti-
cles, respectively. Fractions 8–10 were pooled, pelleted
by ultracentrifugation (31,000 rpm for 45 minutes) and
lysed with 1% SDS. Typical protein yields of 2–5 mg/ml
were obtained and the samples were subjected to SDS-
PAGE and Western blot analysis. Production of virus in
MT-4 cells was achieved through infection with WT
NL4.3 virus. For the purification, the same protocol
was followed as for purification of virus produced in
293T cells.
Ellman acetylcholine esterase activity assay
To evaluate the virus purification procedure and in par-
ticular the separation of exosomes from virus particles,
we optimized a previously described assay [35,54].
Acetylcholinesterase (AChE) hydrolyzes acetylthiocho-
line into thiocholine and acetate. The assay measures
the activity of AChE present in intact microvesicles by
quantifying the absorbance at 405 nm. 100 μl of the frac-
tions were transferred to 96-well plates and incubated at
37°C for 10 minutes. Then 100 μl of a mixture of 100
mM sodium phosphate buffer, pH 8.0, 75 mM acet-
ylthiocholine iodide substrate (Sigma) and 10 mM 5, 5′-
dithiobis-2-nitrobenzoic acid (Ellman’s reagent, DTNB,
Sigma) in a ratio of 150:2:5 was added to each well and
incubated for an extra 10 minutes at 37°C. The plates
were read using the Perkin Elmer Envision platform at
405 nm.
Semi-quantitative p24 ELISA
To define HIV-1 particle containing fractions and
control purification efficiency, we performed a semi-
quantitative p24 ELISA on the fractions using the Alli-
ance HIV-1 p24 ELISA kit (Perkin Elmer). For this assay,
we boiled 50 μl of each fraction at 95°C for 5 minutes
prior to transfer to immunosorbent 96-well plates
(NUNC, Denmark). After sealing the plates were incu-
bated overnight at 4°C. Next, we removed the super-
natant and blocked non-specific signal with 5% donkey
serum for 30 minutes at room temperature. The subse-
quent experimental procedures and plate reading were
performed following the manufacturer’s instructions.
In vitro HIV-1 protease (PR) assay and detection of the
cleavage products
Affinity purified recombinant HIV-1 PR was a kind gift
from Dr. P. Řezáčová, Institute of Organic Chemistry
and Biochemistry, Academy of Sciences of the Czech Re-
public. 20 μg of purified recombinant (Flag)-LEDGF/p75
protein was incubated with 2 μg HIV-1 PR in 50 μl reac-
tion buffer (50 mM sodium acetate buffer; pH 4.9, 200
mM NaCl and 0.002% BSA) for 2 h at 37°C. The specifi-
city of proteolysis was controlled by incubating HIV PR
with different concentrations of RTV (2.5-50 μM) for 30
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order and kinetics of LEDGF/p75 proteolytic cleavage,
we followed proteolysis over time and analyzed the pro-
tein bands. In all cases, PR was immediately inactivated
by adding Laemmli loading buffer and heating at 98°C
for 3–5 minutes and the mixtures were separated using
4-12% SDS-PAGE. Bands were visualized either by Coo-
massie staining or by Western blotting using anti-LEDGF/
p75 (A300-848A, Bethyl Laboratories. Inc, recognizing aa
480–530) or anti-Flag antibody (detects fragments with
intact N-terminus). N-terminal sequence analysis of the
cleaved LEDGF/p75 derivatives was performed after
blotting on PVDF membrane and staining with Coo-
massie brilliant blue. Individual bands were cut from
the membrane, destained in methanol and the amino
acid sequence was determined after elution of each
band and subjected to by automated Edman degrad-
ation using a capillary 491cLC protein sequencer (Ap-
plied Biosystems).
To evaluate the effect of subtilisin on purified LEDGF/
p75, 20 μg Flag-LEDGF/p75 was incubated 0, 2 or 18
hours with 13.33 ng (1:1500 enzyme to substrate ratio)
or 25 μg (1:0.8 enzyme to substrate ratio) of subtilisin in
50 μl reaction buffer (20 mM Tris–HCl pH 8.0, 150 mM
NaCl and 1 mM CaCl2). Inactivation and visualization
was performed as described for the PR assay. To evaluate
the effect of subtilisin on LEDGF/p75 absorbed to the vir-
ion surface, NL4.3 virus was pelleted, spiked during 4
hours with or without 40 μg Flag-LEDGF per 100 μL of
virus and treated with or without subtilisin (1mg/mL) in
subtilisin reaction buffer during 18 hours. Western blot-
ting was performed as described above.
Purification of recombinant proteins
GST-sPol_PRD25N, His-MBP-sPol_PRD25N, Flag-LEDGF/
p75 WT and Flag-LEDGF/p75D366N were purified as de-
scribed before [9,30]. MBP was purchased from New
England Biolabs.
AlphaScreen protein-protein interaction assay
AlphaScreen (PerkinElmer) is a bead-based technology
that allows studying biomolecular interactions. Briefly,
all proteins, compound controls and beads were diluted
to their respective working stocks in assay buffer (25
mM Tris/HCl pH 7.5, 150 mM NaCl, 1 mM dithiothre-
itol, 1 mM MgCl2 0.1% (w/V) BSA, 0.1% (V/V) Tween
20). 5 μL buffer/compound, 5 μL GST-Pol_PRD25N and
5 μL Flag-LEDGF/p75 were added to wells of a 384-
well OptiPlate (PerkinElmer). The plate was sealed and
left to incubate for 1 h at 4°C. Next, 10 μL of a mix of
glutathione donor and anti-Flag acceptor AlphaScreen
beads was added (20 μg/mL final each), the plate was
resealed and incubated for 1 more hour at 23°C. Alpha
signal was read out on an EnVision Multilabel plate reader(PerkinElmer) and data were analyzed using Prism 5.0
(GraphPad).
For the titration experiments, GST-sPol_PRD25N was
used at a constant concentration of 20 nM while WT
and D366N Flag-LEDGF/p75 were titrated from 50 nM
downward in a 1:2.5 dilution series. In the compound
competition assays, both GST-Pol_PRD25N and WT
Flag-LEDGF/p75 were kept constant at 20 and 5 nM re-
spectively and CX05045, raltegravir or DMSO were ti-
trated in a 1:2 dilution series starting at 100 μM.
Pull-down assays
5 μg Flag-tagged LEDGF/p75WT and LEDGF/p75D366N
were first bound to anti-Flag M2 Affinity Gel (Sigma) and
incubated 10 minutes on ice. The slurry was then incu-
bated for 4 hours with 10μg of His-MBP- sPol_PRD25N or
MBP in 250 μL binding buffer (25 mM Tris pH 7.4, 150
mM NaCl, 0.1% NP40, 1 mM MgCl2, 2 mM DTT).
After washing 3 times with wash buffer (25 mM Tris
pH 7.4, 300 mM NaCl, 0.1% NP40, 1 mM MgCl2, 2 mM
DTT), the proteins bound to the beads were eluted with
elution buffer (binding buffer with 1% SDS) and were
subjected to SDS-PAGE analysis and visualized by Coo-
massie staining.
Gel electrophoresis and immunoblot analysis for
LEDGF/p75 uptake in virions
Protein samples were prepared in 1% SDS. Next, 30 μg
of total protein content was loaded in each sample lane
and proteins were separated by SDS-PAGE (4-12% bis-
tris or 12.5% tris-glycine). For LEDGF/p75 and HIV-1
IN quantification a dilution series of recombinant Flag-
tagged LEDGF/p75 or His-IN was loaded next to re-
spectively 30 μg of viral lysate for LEDGF/p75 detection,
15 μg for eGFP-LEDGF325–530 detection or 7.5 μg for IN
detection, purified and concentrated as described above.
Protein markers were PageRuler Prestained Protein Lad-
der and PageRuler Prestained Protein Ladder from Ther-
moScientific. Proteins were detected with the respective
antibody: rabbit anti-LEDGF/p75 (1:100 for viral lysate
and 1:1000 for cell lysate, Bethyl Laboratories. Inc), mouse
monoclonal anti-HIV-1 IN (IN2, 1:10,000 for viral lysates
and 1:2000 for cell lysates, Abcam), mouse anti-HIV-1
CA (1:10,000, AIDS reagents Program). Visualization
was performed using chemiluminescence (Pierce ECL,
Thermo Scientific).
Electron microscopy
Negative staining EM was performed with 50 μl of inac-
tivated virus fractions applying the grid on drop method
(Laue and Bannert 2010). Four hundred mesh copper
grids (Plano, Wetzlar, Germany) filmed with pioloform
were coated with carbon and were glow-discharged to
increase hydrophilicity and particle adherence before
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After washing in 5 droplets of water, grids were stained
with 1% phosphortungstic acid, pH 7.2 and analyzed
with a TEM (Tecnai 12 BioTwin, FEI). For thin section
EM. 1×106 Nalm-6 cells were infected with the NL4.3
for 2 days and then washed with PBS and incubated with
fresh medium. 30 hours post washing, cells were pelleted
and fixed overnight at 4°C with 2.5% glutaraldehyde. Cell
pellets were post-fixed with OsO4 (1% in ddH2O; Plano,
Wetzlar, Germany), block-stained with uranyl acetate (2%
in ddH2O; Merck, Darmstadt, Germany), dehydrated
stepwise in graded alcohol, immersed in propylenoxide
and embedded in Epon (Serva, Heidelberg) with polymer-
isation at 60 °C for 48 h. Ultrathin sections (60–80 nm)
were cut using an ultramicrotome (Ultracut S or UCT;
Leica, Germany) and stained with 2% uranyl acetate and
lead citrate. Transmission electron microscopy was per-
formed with an EM 902 (Zeiss) operated at 80 kV and the
images were digitised using a slow-scan charge-coupled-
device camera (Pro Scan; Scheuring, Germany).
Additional files
Additional file 1: Figure S1. Effect of subtilisin on LEDGF/p75
proteolysis. (A) Coomassie stained SDS-PAGE gel showing that LEDGF/
p75 degradation by subtilisin is not inhibited by ritonavir (RTV). Lane 1-3:
Limited proteolysis of LEDGF/p75 (20 μg) was performed at 37°C for different
time intervals (0-2-18 hours) with 13.33 ng of subtilisin (1:1500 (w/w) ratio of
enzyme to substrate). Lane 4: the proteolysis was performed for 18 hrs using
1 mg/ml subtilisin (enzyme to substrate ratio 1:0.8); this concentration was
used during virus purification. Bands representing BSA and subtilisin are
indicated with arrowheads. (B) Western blot analysis with anti-Flag antibody
of subtilisin treated virus preparations spiked with recombinant Flag-LEDGF/
p75. NL4.3 was spiked 4 hours with buffer (lane 1) or Flag-LEDGF/p75 (lane
2, 3) at 4°C and subsequently incubated at 37°C for 18 hours with (lane 3) or
without (lane 1, 2) subtilisin.
Additional file 2: Figure S2. Detection of LEDGF/p75 in purified virions
produced in a T-cell line. Supernatant of HIV-1 IIIB (lane 1) and mock infected
(lane 2) MT-4 cells was harvested, treated with subtilisin and purified over an
iodixanol velocity gradient. (A) Acetylcholinesterase (AchE) activity and p24
content of the different fractions show an effective separation of exosomes
and HIV virions. (B) Fractions 8-10 were pooled and subjected to Western
blot analysis using anti-LEDGF/p75, anti-IN or anti-CA antibody.
Additional file 3 Table S1. LEDGF/p75 peptides detected from purified
HIV virions using Mass Spectrometry. Table S2. Determination of the
molecular mass of LEDGF/p75 fragments generated by HIV-1 PR in vitro.
Table S3. N-terminal sequencing of LEDGF/p75-derived fragments following
HIV-1 PR digestion. Table S4. Identified cleavage site sequences and
cleavage prediction algorithm of octapeptides derived from LEDGF/p75
cleavage by HIV-1 PR.
Additional file 4: Figure S3. LEDGF/p75 detected in purified HIV
virions using Mass Spectrometry. Peptides described in Additional file 3:
Table S1 mapped to LEDGF/p75. Confirmed (red) and predicted (orange)
protease cleavage sites are indicated, as well as the integrase interacting
D366 amino acid (blue). Protease cleavage sites were predicted with
HIVcleave [38,55].
Additional file 5: Figure S4. In vitro limited proteolysis of LEDGF/p75
by HIV-1 PR and determination of molecular mass of cleavage products
generated by HIV-1 PR. (A, B) HIV-1 PR cleavage products of pure recombinant
Flag-LEDGF/p75 separated by SDS-PAGE. Coomassie brilliant blue staining
(A) revealed the same cleavage pattern as untagged LEDGF/p75, while
Western blot analysis (B) using anti-Flag antibody recognized N-terminalfragments or C-terminal fragments using anti-LEDGF/p75 antibody. Bands
representing BSA and HIV-1 PR are indicated with arrowheads. (C) Cleavage
of recombinant His-MBP-sPol_PRD25N by recombinant HIV-PR is inhibited by
high concentrations of ritonavir (RTV). (D) Standard curve generated from
the reference protein marker bands (R2 = 0.9982) as described before [1].
Molecular mass (kDa) of the different fragments of LEDGF/p75 and reference
full-length proteins are indicated on the standard curve.
Additional file 6: Figure S5. Characterization of the expression of
different LEDGF/p75 constructs. (A, B, C) LEDGF/p75-depleted cells (LEDGF/
p75KD) were back-complemented with lentiviral vectors encoding either
Flag-LEDGF/p75 (LEDGF/p75BC) or Flag-LEDGF/p75BCD366N. (A) Fluores-
cence microscopy images of cells stained with anti-LEDGF/75 antibody (red).
Nuclei were stained with DAPI (blue). The levels of protein and mRNA
for the different LEDGF/p75 constructs were determined by RT-qPCR (B)
and Western blot analysis (C), respectively. β-tubulin was included as a
loading control. (D, E, F) Stable overexpression of eGFP-LEDGF325-530 or
eGFP-LEDGF325-530D366N in 293T cells verified with (D) fluorescence
microscopy (anti-LEDGF/p75 antibody: red; eGFP: green; DAPI: blue), (E)
RT-qPCR or (F) Western blotting (LEDGF/p75: black arrowhead,
eGFP-LEDGF325-530: open arrowhead).
Additional file 7: Figure S6. Quantification of LEDGF/p75 or eGFP-
LEDGF325-530 in HIV particles. (A, B) Western blot of recombinant
Flag-LEDGF/p75 (upper lanes) or His-IN (lower lanes) in a 1:3 dilution series,
next to HIV virions harvested, subtilisin treated, purified and concentrated
from WT 293T cells (A) or cells overexpressing eGFP-LEDGF325-530 or
eGFP-LEDGF325-530D366N (B) using anti-LEDGF/p75 (upper lanes) or
anti-IN (lower lanes) antibody.
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